Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Saxagliptin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 16,017Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 11Onglyza

    02 6Onglyza/Kombiglyze XR/Komboglyze

    03 1Onglyza/Kombiglyze XR/Komboglyze

    04 1Onglyza/Kombiglyze Xr/Komboglyze

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Onglyza/Kombiglyze XR/Komboglyze

    Metoprolol Hydrochloride

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Onglyza/Kombiglyze XR/Komboglyze

    United Kingdom
    arrow
    2024 ACI Convention
    Not Confirmed

    AstraZeneca

    Metoprolol Hydrochloride

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 470

    2019 Revenue in Millions : 527

    Growth (%) : -11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Onglyza/Kombiglyze XR/Komboglyze

    Saxagliptin/Saxagliptin

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Onglyza/Kombiglyze XR/Komboglyze

    United Kingdom
    arrow
    2024 ACI Convention
    Not Confirmed

    AstraZeneca

    Saxagliptin/Saxagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 470

    2019 Revenue in Millions : 527

    Growth (%) : -11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Onglyza

    Saxagliptin

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Onglyza

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Kyowa Kirin

    Saxagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 65

    2019 Revenue in Millions : 70

    Growth (%) : -7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Onglyza/Kombiglyze XR/Komboglyze

    Saxagliptin

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Onglyza/Kombiglyze XR/Komboglyze

    United Kingdom
    arrow
    2024 ACI Convention
    Not Confirmed

    AstraZeneca

    Saxagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 360

    2020 Revenue in Millions : 470

    Growth (%) : -23

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Onglyza/Kombiglyze XR/Komboglyze

    Saxagliptin

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Onglyza/Kombiglyze XR/Komboglyze

    United Kingdom
    arrow
    2024 ACI Convention
    Not Confirmed

    AstraZeneca

    Saxagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 360

    2020 Revenue in Millions : 470

    Growth (%) : -23

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Onglyza

    Saxagliptin

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Onglyza

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Kyowa Kirin

    Saxagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 52

    2020 Revenue in Millions : 65

    Growth (%) : -10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Onglyza

    Saxagliptin

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Onglyza

    United Kingdom
    arrow
    2024 ACI Convention
    Not Confirmed

    AstraZeneca

    Saxagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 257

    2021 Revenue in Millions : 360

    Growth (%) : -29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Onglyza

    Saxagliptin

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Onglyza

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Kyowa Kirin

    Saxagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 39

    2021 Revenue in Millions : 52

    Growth (%) : -25

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Onglyza

    Saxagliptin

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Onglyza

    United Kingdom
    arrow
    2024 ACI Convention
    Not Confirmed

    AstraZeneca

    Saxagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 257

    2021 Revenue in Millions : 360

    Growth (%) : -29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Onglyza

    Saxagliptin

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Onglyza

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Kyowa Kirin

    Saxagliptin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2023 Revenue in Millions : 29

    2022 Revenue in Millions : 39

    Growth (%) : -17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF